Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Understanding Neurogenic AMC

At a Glance

Neurogenic Arthrogryposis Multiplex Congenita (AMC) causes joint contractures at birth due to nervous system development issues. While the neurological cause is usually non-progressive, the joint tightness requires lifelong management through physical therapy, splinting, and sometimes surgery.

Receiving a diagnosis of Neurogenic Arthrogryposis Multiplex Congenita (AMC) is often an experience filled with shock and a flood of complex information. It is important to know that your emotional reaction to this rare, life-altering diagnosis is completely valid [1][2].

What is Neurogenic AMC?

Neurogenic AMC is not a single disease. Instead, it is a clinical term used to describe a condition where a child is born with contractures (permanent tightening of muscles, tendons, or joints that prevents normal movement) in two or more areas of the body [3][4].

In the “neurogenic” form, these contractures occur because of a problem with the developing nervous system—such as the spinal cord or peripheral nerves [5][6]. This neurological issue leads to fetal akinesia (significantly reduced movement in utero) [7][8]. Because the joints cannot move freely during fetal development, they become fixed in specific positions [4].

Unlike “classic” AMC (often called Amyoplasia, which primarily affects muscle development), Neurogenic AMC is rooted in how the nervous system communicates with the muscles [9][5].

Three Stabilizing Facts

In the midst of a new diagnosis, it helps to ground yourself in these three fundamental truths:

  1. The underlying condition is typically non-progressive, but contractures require lifelong management. This means the neurological disease itself does not biologically “get worse” over time [4]. However, the joint contractures themselves can and often do progress, recur, or worsen as bones grow if not continuously managed with stretching and splinting. (Note: In very rare genetic cases, such as mutations in the CNTNAP1 gene, the underlying neurological symptoms can be progressive [10][11]. Your medical team will use testing to determine the specific type.)
  2. Targeted treatments are highly effective. Because AMC is a symptom of an underlying issue, medical teams focus on improving function through a multidisciplinary approach [12][13]. This includes intensive physical and occupational therapy to improve range of motion, and occasionally orthopedic surgeries to align joints for better mobility [14][15].
  3. Genetic testing is advancing rapidly. Medical science can now identify specific genetic causes for Neurogenic AMC more accurately than ever before [9][16]. Identifying the exact gene involved helps doctors move beyond a general description and create a personalized “roadmap” for your care and future [16][17].

Common Misconceptions

Understanding what AMC is not can be just as helpful as understanding what it is:

  • Misconception: It’s just a muscle problem. While muscles are affected, in Neurogenic AMC, the root cause is the nervous system’s inability to signal those muscles to move during development [5].
  • Misconception: All AMC is the same. AMC is a “big tent” term for many different conditions [3]. Two people with AMC may have very different underlying causes, levels of independence, and long-term outlooks [9][18].
  • Misconception: No movement in the womb means it’s AMC. While reduced movement causes the contractures, many mothers report that they did feel some fetal movement [19]. The diagnosis is based on the presence of the contractures at birth, not just the perception of movement.

Navigating the Path Ahead

Your journey will involve a team of specialists, including neurologists, orthopedic surgeons, and therapists [12]. The goal of this multidisciplinary care is to maximize independence and quality of life [17]. While the diagnosis is complex, the focus is always on abilities and supporting development every step of the way.

Common questions in this guide

What is Neurogenic AMC?
Neurogenic AMC is a condition where a baby is born with permanent tightening of joints, known as contractures, in two or more areas of the body. It is caused by an underlying issue in the developing nervous system that limits the baby's movement in the womb.
Is Neurogenic AMC a progressive disease?
In most cases, the underlying neurological condition causing Neurogenic AMC is non-progressive, meaning the nerve issue itself does not worsen over time. However, the joint contractures can become tighter as a child's bones grow if they are not consistently managed with stretching and therapy.
How is Neurogenic AMC treated?
Treatment requires a multidisciplinary approach focused on maximizing your child's independence and mobility. This typically involves intensive physical and occupational therapy, stretching, splinting, and occasionally orthopedic surgery to better align the joints.
Why is genetic testing recommended for Neurogenic AMC?
Because Neurogenic AMC is a broad clinical term with many potential causes, genetic testing helps pinpoint the specific gene mutation responsible for your child's condition. Identifying the exact cause allows doctors to create a highly personalized and accurate care plan.
What is the difference between Neurogenic AMC and Classic AMC?
While both conditions result in joint contractures at birth, they have different root causes. Classic AMC, often called Amyoplasia, primarily involves abnormal muscle development. Neurogenic AMC, on the other hand, stems from a problem with how the nervous system communicates with those muscles.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is the AMC considered 'static' (non-progressive) or is it associated with a rarer 'progressive' genetic type?
  2. 2.What specific genetic testing do you recommend to identify the underlying cause of the neurogenic presentation?
  3. 3.Based on the initial assessment, what are the primary goals for mobility and independence in the first year?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    The experience of caregiving for children with rare musculoskeletal conditions: a qualitative study in arthrogryposis multiplex congenita.

    Elekanachi RU, Lajoie A, Tavukcu S, et al.

    Orphanet journal of rare diseases 2024; (19(1)):235 doi:10.1186/s13023-024-03224-8.

    PMID: 38877508
  2. 2

    Health-related quality of life in 205 children with arthrogryposis multiplex congenita.

    Nematollahi S, Rampakakis E, Amara M, et al.

    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2025; (34(1)):247-260 doi:10.1007/s11136-024-03808-8.

    PMID: 39436578
  3. 3

    Arthrogryposis is a descriptive term, not a specific disease entity: Escobar Syndrome is an example.

    Al Kaissi A, Ryabykh S, Ochirova P, et al.

    Minerva pediatrics 2024; (76(1)):30-36 doi:10.23736/S2724-5276.20.05796-5.

    PMID: 32536119
  4. 4

    Arthrogryposis multiplex congenita-an update.

    Møller-Madsen B

    Journal of children's orthopaedics 2015; (9(6)):425-6 doi:10.1007/s11832-015-0688-2.

    PMID: 26482521
  5. 5

    Fetal Akinesia/Hypokinesia and Arthrogryposis of Neuromuscular Origin: Etiologic Groups, Genetics, and Phenotypic Spectrum.

    Pérez-Vidarte F, Estévez-Arias B, Matalonga L, et al.

    Annals of clinical and translational neurology 2025; (12(8)):1528-1547 doi:10.1002/acn3.70088.

    PMID: 40443119
  6. 6

    Genetic Bases of Arthrogryposis Multiplex Congenita.

    Melki J

    Annual review of genomics and human genetics 2026; doi:10.1146/annurev-genom-120324-031410.

    PMID: 41729706
  7. 7

    Congenital Zika syndrome with arthrogryposis: retrospective case series study.

    van der Linden V, Filho EL, Lins OG, et al.

    BMJ (Clinical research ed.) 2016; (354()):i3899 doi:10.1136/bmj.i3899.

    PMID: 27509902
  8. 8

    Intra-familial variability associated with recessive RYR1 mutation diagnosed prenatally by exome sequencing.

    Casey J, Flood K, Ennis S, et al.

    Prenatal diagnosis 2016; (36(11)):1020-1026 doi:10.1002/pd.4925.

    PMID: 27616680
  9. 9

    A review of the orthopedic interventions and functional outcomes among a cohort of 114 children with arthrogryposis multiplex congenita.

    Hansen-Jaumard D, Elfassy C, Montpetit K, et al.

    Journal of pediatric rehabilitation medicine 2020; (13(3)):263-271 doi:10.3233/PRM-190657.

    PMID: 33104047
  10. 10

    Absence of Axoglial Paranodal Junctions in a Child With CNTNAP1 Mutations, Hypomyelination, and Arthrogryposis.

    Conant A, Curiel J, Pizzino A, et al.

    Journal of child neurology 2018; (33(10)):642-650 doi:10.1177/0883073818776157.

    PMID: 29882456
  11. 11

    Expansion of the GLE1-associated arthrogryposis multiplex congenita clinical spectrum.

    Smith C, Parboosingh JS, Boycott KM, et al.

    Clinical genetics 2017; (91(3)):426-430 doi:10.1111/cge.12876.

    PMID: 27684565
  12. 12

    Characterization of a group unrelated patients with arthrogryposis multiplex congenita.

    Valdés-Flores M, Casas-Avila L, Hernández-Zamora E, et al.

    Jornal de pediatria 2016; (92(1)):58-64.

    PMID: 26453511
  13. 13

    Arthrogryposis multiplex congenita with maxillofacial involvement: a case report.

    Cirillo S, Regge D, Garagiola U, et al.

    Maxillofacial plastic and reconstructive surgery 2023; (45(1)):10 doi:10.1186/s40902-023-00378-6.

    PMID: 36752944
  14. 14

    Long-term outcome for patients with arthrogryposis multiplex congenita.

    Dubousset J, Guillaumat M

    Journal of children's orthopaedics 2015; (9(6)):449-58 doi:10.1007/s11832-015-0692-6.

    PMID: 26499455
  15. 15

    Short-term results of early (before 6 months) open reduction of dislocated hips in arthrogryposis multiplex congenita.

    Aydin BK, Yilmaz G, Senaran H, Durgut F

    Journal of pediatric orthopedics. Part B 2016; (25(6)):509-13 doi:10.1097/BPB.0000000000000371.

    PMID: 27392301
  16. 16

    Postnatal Diagnostic Workup in Children With Arthrogryposis: A Series of 82 Patients.

    Chareyre J, Neuraz A, Badina A, et al.

    Journal of child neurology 2021; (36(12)):1071-1077 doi:10.1177/08830738211022972.

    PMID: 34410827
  17. 17

    Rehabilitation in Patients Diagnosed with Arthrogryposis Multiplex Congenita: A Systematic Review.

    García Aguilar CE, García-Muñoz C, Carmona-Barrientos I, et al.

    Children (Basel, Switzerland) 2023; (10(5)) doi:10.3390/children10050768.

    PMID: 37238316
  18. 18

    Arthrogryposis Multiplex Congenita.

    Langston S, Chu A

    Pediatric annals 2020; (49(7)):e299-e304 doi:10.3928/19382359-20200624-01.

    PMID: 32674167
  19. 19

    Maternal experience of fetal movements from a child with AMC: MECA survey.

    Arduç A, Linskens IH, Dussa CU, et al.

    Early human development 2025; (207()):106308 doi:10.1016/j.earlhumdev.2025.106308.

    PMID: 40480018

This page provides educational information about Neurogenic AMC. It does not replace professional medical advice from your child's pediatric neurologist or orthopedic care team.

Get notified when new evidence is published on Neurogenic arthrogryposis multiplex congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.